Advanced Search

Submit Manuscript

Volume 32, No 5, May 2022

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 32 Issue 5, May 2022: 423-424


Banking on metabolomics for novel therapies in TNBC

Aurelien Tripp , George Poulogiannis*

Signalling and Cancer Metabolism Team, Division of Cancer Biology, The Institute of Cancer Research, London, UK
Correspondence: George Poulogiannis(

Despite sharing the lack of hormone receptors and HER2 amplification used to guide therapeutic decisions, Triple-Negative Breast Cancer (TNBC) is a highly heterogeneous subset of breast cancer. In a recent study published in Cell Research, Xiao et al. highlight the opportunity of using this tumor subtype’s metabolic signatures to better stratify patients and identify more effective therapeutic strategies in TNBC.


Browse 148